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Actually it has not quite happened yet, but almost imperceptibly, by degrees,we are learning
to live with cancer.The “War on Cancer,” although generally successful in the pediatric pop-
ulation, has gradually been replaced with a kinder, gentler treatment paradigm that strives
to contain and maintain with stalemate over checkmate, a strategy that may literally con-
stitute the path to least resistance. The purpose of this review is (1) to critically examine
the War on Cancer as a powerfully evocative metaphor that is directly responsible for a
counterproductive and even potentially dangerous war-like cell-kill treatment paradigm, (2)
to suggest that a reframing of this metaphor in less retaliatory and aggressive terms along
with a shift in clinical practice from a maximalist to a minimalist strategy is more appro-
priate to the treatment of cancer, and (3) to draw on examples from the military sector
as points of reference and comparison that closely parallel the three therapeutic “control
and containment” strategies discussed in this review: (1) “Optimox-like” trial designs, (2)
epigenetic modulation, and (3) metronomic dosing.
Keywords: RRx-001, military, epigenetic modulation, metronomic dosing, Optimox, war on cancer
INTRODUCTION
Actually it has not quite happened yet, but almost imperceptibly,
by degrees, we are learning to live with cancer.
As improbable and counterintuitive as it sounds, the scorched
earth, win-at-all-costs ethos from the “War on Cancer,” although
generally successful in the pediatric population, has gradually been
replaced with a kinder, gentler treatment paradigm that strives to
contain and maintain with stalemate over checkmate, a strategy
that may literally constitute the path to least resistance.
The live-and-let-live handwriting is already on the wall with
strategies that include “Optimox-like” trial designs, metronomic
dosing, and epigenetic modulation, discussed in this review; the
reality, largely unacknowledged though it may be, is that the war on
cancer may not be winnable in the majority of cases, as currently
waged.
Chemotherapy and radiation are the ultimate stress test for can-
cer cells, leading to an unintended “survival of the fittest” response
in which the most sensitive cells are culled from the treatment-
resistant herd; inevitably the price of this selection pressure is the
emergence of acquired resistance and therapeutic failure, making
aggressive therapy a self-defeating process. Nature abhors a vac-
uum and fills it up with resistant tumor cells, which ultimately
dooms the outcome to failure.
Abbreviations: CO, conventional oxaliplatin; CONcePT, Combined Oxaliplatin
Neurotoxicity Prevention Trial; CRC, colorectal cancer; GBM, glioblastoma; HCC,
hepatocellular carcinoma; H&W, Drs. Hannahan and Weinberg; IO, intermittent
oxaliplatin; LDM, low dose metronomic; MTD, maximally tolerated dose; NSCLC,
non-small cell lung cancer; OS, overall survival; QOL, quality of life; SCLC, small
cell lung cancer.
This is not to sound a pessimistic or defeatist note; to the
contrary, it may be finally possible to imagine a world in the
not-too-distant future when cancer is a chronic disease like HIV,
COPD, or diabetes: if total eradication is impossible, except in
certain circumstances, due to the development of acquired resis-
tance, then one alternative is simply to hold the line: to box-in the
tumor cells with a discrete, focused strategy of containment, a path
between the extremes of all-out assault and appeasement, thereby
turning metastatic cancer from a death sentence into a chronic
disease.
The purpose of this review is (1) to critically examine the War
on Cancer as a powerfully evocative metaphor that implies the
promise of complete victory, motivates an overly strong desire to
retaliate (“hit hard, hit fast, and hit often” in the words of Admiral
Halsey) and is directly responsible for a counterproductive and
even potentially dangerous war-like cell-kill treatment paradigm,
(2) to suggest that a reframing of this metaphor in less retalia-
tory and aggressive terms along with a shift in clinical practice
from a maximalist to a minimalist strategy is more appropriate
to the treatment of cancer, and (3) to draw on examples from the
military sector as points of reference and comparison that closely
parallel the three therapeutic “control and containment” strate-
gies discussed in this review: (1) “Optimox-like” trial designs, (2)
epigenetic modulation, and (3) metronomic dosing. This review
is warranted if only because the central tenet of the War on Can-
cer, tumor eradication, has remained essentially invariant for over
40 years despite the fact that, by and large, it has not succeeded.
In American strategic language, rollback is the doctrine that
advocates regime change, by force if necessary (1). On the other
end of the spectrum is containment, the application of judicious
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counterforce to prevent expansion. Proposed by a mid-level Amer-
ican diplomat, George F. Kennan, containment, which eschews
rollback, was the cornerstone of the U.S.-Soviet policy to con-
tain Russian expansive tendencies and prevent the cold war from
turning hot (2).
Ever since Nixon’s War on Cancer declaration in 1971 (3)
(though he never actually used that phrase), the majority of
the medical profession has pursued the opposite approach and
endorsed rollback not containment or the taking up of therapeu-
tic arms against cancer to wipe it out in the same way that it has
wiped out polio or smallpox. (Ironically, Nixon withdrew from
Vietnam, only to have entered another war with cancer.) Since the
war trope is clearly here to stay (witness the persistence of the War
on Drugs, War on Poverty, War on Malaria, etc.), different military
examples are cited herein to add perspective and context and to
frame the discussion about the therapeutic examples highlighted
in this review.
War brings with it a set of assumptions and these assumptions
have dominated the discourse and infused the landscape of cancer
treatment for over 40 years. The pharmaceutical industry talks in
combative terms of weapons, targets, arsenals, armamentariums,
therapeutic bull’s-eyes, silver bullets, and magic bullets; patients
are“warriors”encouraged to“win the fight/crusade against cancer”
and “conquer the disease” and oncologists, described as “cancer
warriors or fighters,” attempt to achieve a maximal and rapid cell
killing. Cancer drugs are still currently developed through this 40-
year old system, to achieve the maximally tolerated dose (MTD),
as if cancer were an enemy to be defeated through a massive or
overwhelming display of force. Based on the fervor with which it
is conducted, the War on Cancer seems closer to a hyper-aggressive
military campaign than a treatment trope. Slowly, however, with
the recognition that the War on Cancer is less a war than a quag-
mire, having, by and large, failed to a deliver on its promise of a
decisive victory (4), less strident and less aggressive strategies have
emerged.
In 2001, the publication of the seminal “Hallmarks of Can-
cer” by Drs. Hannahan and Weinberg (H&W), which refined the
War on Cancer metaphor into a series of six unifying principles
that control cell growth and metastasis and ushered in the era
of targeted therapies challenged the medical community to take
stock and recognize that the only way to defeat cancer was to bet-
ter understand it. History’s timeless lesson from as far back as Sun
Tzu, the Chinese general from the sixth century, is that the success-
ful outcome of war critically depends on accurate intelligence and
knowledge of the enemy. The H&W war doctrine describing the
strengths and perhaps weaknesses of Mankind’s enemy (cancer)
was updated and expanded in 2011 (5).
Quagmires, defined as impasses or deadlocks, have occurred
repeatedly in the context of military and evolutionary conflicts
where one side is a much more pronounced orchestrator of pres-
sure. This pressure forces or induces the other side to evolve coun-
termeasures to resist it. Thus, in Vietnam, Iraq, and Afghanistan
(6), it was the U.S. that brought to bear overall superiority of man-
power and firepower, creating a strong selection pressure for the
enemy to evolve, adapt, and survive; this adaptation led to a vicious
cycle of measures – countermeasures and a long, drawn-out war,
in other words, a quagmire. In his book, “Learning to Eat Soup
with a Knife,” a title based on the T. E. Lawrence (Lawrence of
Arabia) observation about the conduct of guerilla warfare, Lieu-
tenant Colonel John Nagl makes the case that the inability of the
U.S. Army to adapt their tactics at the same rate as the Vietnamese,
despite technological superiority, resulted in its failure to defeat
the communist insurgency (7).
Likewise, in the case of cancer, the lethal force of chemotherapy,
designed to wipe out the tumor, may actually have the opposite
effect: the chemosensitive cells, which normally keep the chemore-
sistant forms in check,by competing for scarce space and resources,
are killed off. Cancerous tumors adapt in Darwinian fashion to
their environment and evolve by clonal expansion and genetic
diversification (8). As a result, the tumor emerges more treatment
resistant than it was before (Figure 1).
Cancer is by no means monolithic; rather, it is a highly diverse
and heterogeneous population of cells, with different degrees of
overall fitness, even within a single tumor due to both genetic and
environmental factors (9). In general, the most drug-susceptible
cancer cells are located in the outer rim due to their proximity to
vascularization. In contrast, like the Taliban and Al-Qaeda fighters
in Afghanistan, who hide out and hole up in a complex warren of
cave bunkers, the cancer cells in the inner regions of the tumor
are able take refuge in hypoxic crevices and burrows created by an
FIGURE 1 | UntreatedTumor : the development of resistance is
energetically expensive; therefore, the treatment-sensitive cells
predominate in the untreated tumor and, by outcompeting the
treatment-resistant cells for resources and space, inhibit their growth.
“Containment” Strategy : if treatment is optimized for stability rather than
cure, a stable population of treatment-sensitive cells remain which
suppresses the growth of resistant populations and results in prolonged
patient survival. “Kill” Strategy : dose intensive treatment designed to kill a
maximum number of cancer cells preferentially eliminates
treatment-sensitive cells, actually promotes more rapid growth of the
resistant population and leads to treatment failure and poor outcomes
as a result.
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aberrant and dysfunctional tumor vasculature, safe from the pre-
dations of chemotherapy and radiation, which makes them phe-
notypically resistant. If the drug-sensitive clones on the periphery
are preferentially eliminated with radiation and/or chemotherapy,
then it is these resistant subpopulations that prevail and “hijack”
the tumor.
According to the Red Queen hypothesis, a widely used concept
from evolutionary biology, in reference to the character from the
Lewis Carroll novella, “Through The Looking Glass,” who com-
ments to Alice that “it takes all the running you can do, to keep
in the same place,” co-evolution drives continuous adaptation and
counter-adaptation just to stay even (10). Similarly, chemotherapy
and radiation exert a strong selective pressure on the cancer cells
to adapt often resulting in a no-win situation.
And so while the War on Cancer drags on officially without
armistice or quarter unofficially signs of a tactical shift are already
underway, with “Optimox-like” trial designs, epigenetic modula-
tion, and metronomic dosing serving as the basis for discussion in
this review.
OPTIMOX AND “THE SURGE”
The Surge, as it was called, referred to a modest temporary increase
in U.S. troops in 2007 in Iraq to quell an insurgency that was spiral-
ing (surging) out of control, after which Bush’s plan was to return
to pre-surge levels (11). An Obama-led troop surge, which took
place in Afghanistan in 2010 with the limited objective to beat
back the Taliban and Al-Qaeda and disrupt their momentum long
enough for the Afghans to take over the fight (12), set the stage for
the U.S. to withdraw from Afghanistan.
This surge strategy finds parallels in the “stop and go” Opti-
mox 2 trial design (13) to manage oxaliplatin-induced neuropathy,
where six cycles of FOLFOX induction were followed by infusional
FU until tumor regrowth, at which point oxaliplatin was reintro-
duced, resulting in less neurotoxicity with comparable efficacy and
survival.
Variations on this Optimox theme include
• a complete break in treatment after induction therapy until the
tumor begins to regrow
• the modified “stop and go” of the Phase 3 Combined Oxali-
platin Neurotoxicity Prevention Trial (CONcePT) study in
which patients were “on” oxaliplatin for a predefined interval
of 4 months (FOLFOX and bevacizumab) and “off” oxaliplatin
for a predefined interval 4 months (LV5FU2 plus bevacizumab).
Despite early termination, CONcePT, which compared this
intermittent oxaliplatin (IO) schedule to a conventional oxali-
platin (CO) “treat-to- failure” approach, demonstrated an
impressive improvement in PFS from 7.3 months to 12.0 months
with the stop-and-go strategy (14).
In a recent review of stop-and-go clinical trials from 2000
to 2013 entitled, “Continuous versus Intermittent Chemotherapy
Strategies in Metastatic Colorectal Cancer: A Systematic Review
and Meta-Analysis” by Berry et al. the authors concluded that
compared to continuous chemotherapy, the intermittent strategies
did not negatively impact on overall survival (OS) and “either
maintained or improved quality of life (QOL)” (15).
An additional Optimox-like variation, called adaptive therapy,
developed by Gatenby et al. (16) through mathematical model-
ing (a case of math versus malignancy), proposes treatment-for-
stability in lieu of treatment-for-cure (17) to maximize survival.
The premise is that the classic administration of maximum dose
dense chemotherapy on a regular schedule favors the rapid growth
of resistant subpopulations (18). Adaptive therapy advocates a
Goldilocks approach, where the tumor burden is kept at a con-
stant, stable level, not too much, not too little, but just right to
maintain a sufficient number of chemotherapy-sensitive cells to
inhibit the growth of resistant subpopulations. In this way, treat-
ment is intermittent to coincide with spurts in tumor growth, and
the emphasis is on containment not cure (19).
So pervasive and influential is the War on Cancer mindset espe-
cially in the U.S. that patients may refuse sporadic or intermittent
therapy on the basis that it is preferable to hit the tumor hard
and often – it may be for this reason that the Optimox trials were
enrolled in Europe not U.S. – even though continuous treatment
appears to result in pain without gain, i.e., increased toxicity to
patients without improvement in overall survival, compared to a
stop-and-go strategy.
EPIGENETIC MODULATION AS A “SHAPING OPERATION”
At times of war, the act of degrading and softening up an enemy in
support of and in preparation for a decisive assault is called, in mil-
itary parlance, a “shaping operation.” According to the Army Field
Manual 3-0 (20), “A shaping operation is an operation at any eche-
lon that creates and preserves conditions for the success of the decisive
operation. Shaping operations establish conditions for the decisive
operation through effects on the enemy, population (including local
leaders), and terrain. . . Shaping operations may occur throughout
the operational area and involve any combination of forces and
capabilities.”
In many ways a “shaping operation” or, rather, a “re-shaping
operation” describes the tumor remodeling action of the epige-
netic agents, through beneficial re-expression of methylated and
abnormally silenced genes to degrade and reverse resistance to
subsequent therapy.
In a Phase 1/2 clinical trial of double epigenetic blockade
with a combination of 5-azacitidine and entinostat in advanced,
refractory non-small cell lung cancer (NSCLC), several patients
demonstrated sustained and durable responses to their immedi-
ate next line of therapy of 4 years or more following progressive
disease on azacitidine and entinostat (21, 22), leading the authors
to hypothesize that the epigenetic therapy primed the cancer for
response to subsequent treatment.
These observations are in agreement with another Phase 1 trial
with the novel systemically non-toxic epigenetic agent, RRx-001, a
double HDAC, and DMA methyltransferase inhibitor, where five
colorectal cancer (CRC) patients were resensitized to previously
failed FOLFIRI for 6 months or longer post-RRx-001 progres-
sion (23, 24), which suggests that RRx-001 epigenetically disrupts
multiple cellular processes including chemoresistance, possibly
through the de-repression of tumor suppressor genes like p53.
Resensitization of chemorefractory tumors is a focus of several
Phase 2 RRx-001 clinical trials in diverse cancers such as CRC,
hepatocellular carcinoma (HCC), glioblastoma (GBM), NSCLC,
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small cell lung cancer (SCLC), malignant pleural mesothelioma,
gastric and breast carcinomas.
In this way, epigenetic inhibition may represent a “kinder, gen-
tler” approach in which the tumor is “reprogramed” during a
preliminary “run-in” or priming period, similar to the shaping
operation described in the Army Field Manual above, to respond
to subsequent cytotoxic treatment, thereby increasing survival but
not toxicity.
METRONOMIC DOSING AND ECONOMIC SANCTIONS
As an alternative to armed conflict and all-out war, economic
sanctions have played an important role in U.S. foreign policy
throughout the twentieth and twenty-first centuries as a strat-
egy to isolate, destabilize, and cripple “bad actors,” countries with
inimical agendas like Russia, Cuba, Iran, North Korea, Sudan, and
Syria (25).
Metronomic chemotherapy involves regular, frequent systemic
administration (26), i.e., without a rest period of cytotoxic agents
such as cyclophosphamide and methotrexate at lower doses, to
contain rather than kill the tumor via multiple cytostatic mecha-
nisms (27), including the induction of senescence, immunostim-
ulation, and antiangiogenesis, which drain energy and resources,
similar to an embargo, without perpetrating a holocaust on ben-
eficial chemosensitive cells. In a systematic literature analysis of
low dose metronomic (LDM) chemotherapy, Lien et al. concluded
that, despite the lack of definitive Phase 3 trial results and even the
rarity of high quality Phase 2 studies, “LDM appears to be clini-
cally beneficial and safe in a broad range of tumors” (28) including
breast, colon, and gastric cancers. LDM is typically administered
with twice daily weekday on-weekend off (5 days on, 2 days off)
capecitabine (29, 30).
CONCLUSION AND FUTURE PERSPECTIVE
The phrase, The War on Cancer, evokes the liberation of enemy-
held territory and regime-change operations, a kind of C-Day or
“Operation Overkill.” The problem with this image is that it mis-
represents cancer as an enemy that is defeatable when, in fact, in
the case of cancer cells, victory is only achievable with total erad-
ication, which may not be readily possible. The very act of trying
to drive the cancer cells to extinction only succeeds for the most
part in removing the moderates, i.e., the chemosensitive cells, and
leaving behind the extremists, i.e., the chemoresistant cells, which
makes the situation that much more desperate.
A middle course between appeasement and Armageddon is
containment, which takes a long view, and eschews“rollback,” pro-
vided the tumor remains in its box. According to Gatenby et al.
(18), drug-susceptible cancer cells predominate in an untreated
environment, reflecting the extra energy and substrate costs of
the resistance phenotype. While the repeated administration of
MTDs may induce regression or remission, recurrence of even
more malignant tumors usually follows. Akin to the dangers of
bacterial resistance due to antibiotic overuse, an MTD dosing
strategy may constitute overtreatment, which selects for rather
than bypasses resistant phenotypes. In other words, without the
selection pressure from chemotherapy and radiation, sensitive cells
have the upper hand and keep the resistant cells at bay.
Despite this apparent lose–lose, Catch-22 scenario (damned if
you treat, damned if you do not), a third strategy, containment,
presents itself as a solution to keep the “long peace” by turning
cancer into a clinically manageable chronic disease like diabetes or
hypertension, which is controlled but not cured with medication.
Hopefully a state of balance is reached, in which the net result of
tumor growth and destruction is zero or close to zero, resulting in
stabilization or non-progression of disease.
For this reason, a hard line strategy, which emphasizes cure over
coexistence and an all-out war instead of a limited one, may only
force cancer down its projected path to surpass heart disease as
the leading cause of death by 2030 (31) in a kind of self-fulfilling
prophecy. Instead of risking mutual annihilation, mutual survival
demands that we contain and maintain the status quo and thereby
turn a “hot” war into a cold one. Although it may chafe and go
against the grain to play not to lose rather than to win, the strate-
gies discussed herein suggests that with respect to cancer we have
started to do just that, slowly.
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